QS-21 is a highly purified triterpenoid saponin adjuvant used in advanced vaccine research and manufacturing. It is supplied as a defined 35:65 mixture of QS-21-Xyl and QS-21-Api, offering a well-characterized composition for sensitive immunology and formulation work. This product is known for its proven clinical track record and is already approved for use in 5 human vaccines worldwide, making it a valuable choice for developers seeking a clinically relevant vaccine adjuvant with strong translational potential. QS-21 is especially recognized in oncology vaccine development, including melanoma-focused programs, as well as in infectious disease vaccine applications such as HIV, Herpes Simplex, and Tuberculosis. Its high purity and quality positioning as Research grade / GMP grade make it suitable for organizations that require reliable, reproducible material for preclinical studies, process development, and commercial vaccine programs. For B2B buyers, QS-21 is an important specialty immunological ingredient where product consistency, clinical relevance, and source quality matter. It is commonly sought by vaccine manufacturers, biotech companies, research institutions, and contract development organizations working on next-generation immunotherapies and prophylactic vaccines. With a low MOQ of 1, it supports procurement flexibility for evaluation, development, and scale-up planning.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.